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Abstract: Xanthohumol (XN) is a well-known prenylated flavonoid found in Humulus lupulus L. It is
involved in several pharmacological activities, including the sensitization of doxorubicin-resistant
breast cancer (MCF-7/ADR) cells to doxorubicin (DOX) through a reduction in cell viability and
stemness. In the present study, we revealed another mechanism to further explain the reverse of
the drug resistance of XN. In the MCF-7/ADR cell line, we found that XN inhibited the efflux
functions of ATP-binding cassette subfamily B member 1 (ABCB1). We also observed that XN was
a substrate of ABCB1 and stimulated its ATPase activity. Moreover, our results revealed that XN
showed a synergic effect with the ABCB1 substrate colchicine (COL) in the MCF-7/ADR cell line.
Further, we showed that XN bound to the central transmembrane domain (TMD) site, overlapping
with the DOX binding site. This mechanism was supported by molecular modeling and simulation
data, which revealed that XN bound to the ABCB1 transmembrane domain, where doxorubicin also
binds, and its binding affinity was stronger than that of doxorubicin, resulting in less protein and
ligand position fluctuation. These results support the XN-induced reversal of drug resistance via
the inhibition of ABCB1-mediated transport of doxorubicin, stimulating ABCB1 ATPase activity and
acting as a substrate of ABCB1.
Keywords: xanthohumol; doxorubicin resistance; synergism; ABCB1
1. Introduction
ATP-binding cassette subfamily B member 1 (ABCB1; also known as p-glycoprotein [Pgp]
or multidrug resistance protein 1 [MDR1]) belongs to the family of ABC membrane transporters.
The most studied biological role of ABCB1 is exporting chemically unrelated substrates; therefore,
it is usually involved in MDR to cancer chemotherapy, and the modulation of drug pharmacokinetics
and interactions [1,2]. ABCB1 has different kinds of substrates, ranging in size from 330 Da up to
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4000 Da [1]. Inhibitors of ABCB1, as well as its non-toxic substrates, might be used to overcome
drug resistance and understand the intestinal absorption of drugs. Much effort has been devoted to
screening for natural phytochemicals, which can inhibit ABCB1-mediated transport, and thus have the
potential application of reversing drug resistance [3].
Xanthohumol (XN, Figure 1) is a well-known prenylated flavonoid that exists uniquely in hops
(Humulus lupulus L.), and its general dietary source is beer. As we have reviewed previously, XN has
multiple health benefits, mainly including metabolic syndrome attenuating effects, hepatic protection
effects, antimicrobial activity, anti-parasite effects, cancer chemo-preventive effects, cancer therapeutic
activity [4], and also inhibitory activities in cancer angiogenesis [5,6]. Interestingly, recent studies
have shown that XN could sensitize cancer cells to certain anticancer drugs [7,8]. Moreover, XN
was considered to be an inhibitor of the breast cancer resistance protein (ABCG2) transporter [9].
Considering that both ABCB1 and ABCG2 play a vital role in MDR and share some common substrates,
we investigated whether XN could also be a substrate of ABCB1, which might account for its drug
resistance reversing effects.
Here, for the first time, we identified XN as a new substrate of ABCB1 that competitively inhibits
ABCB1 transport functions, increasing the efficiency of the chemotherapy agent substrates of ABCB1,
e.g., doxorubicin (DOX) and colchicin (COL). Our molecular docking studies further revealed that XN
could bind to ABCB1 with the same binding site of DOX.
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Figure 1. Xanthohumol (XN) molecular structure. 
2. Materials and Methods 
2.1. Reagents and Cells 
Nanjing Spring and Autumn Biological Engineering Co., Ltd., Nanjing, China, provided the 
compound XN. The kit for Pgp-Glo™ ATPase assay was obtained from Promega Corporation, 
Madison, WI, USA. Other materials were purchased from Beyotime Biotechnology, Shanghai, China. 
The doxorubicin resistance MCF-7/ADR cell line was established by increasing DOX concentrations 
in the culture medium of MCF-7 until reaching a concentration of 0.5 μM, as previously described 
[10]. The MCF-7/ADR cell line was cultured at Roswell Park Memorial Institute (RPMI)-1640, 
supplemented with 10% fetal bovine serum (FBS), and maintained in the presence of DOX, penicillin, 
and streptomycin at 37 °C in 5% CO2.  
2.2. Detection of Intracellular DOX Accumulation 
For the intracellular DOX accumulation assay, the MCF-7/ADR cell line was pretreated with 
different concentration of XN (0–20 μM) for 34 h and then co-incubated with DOX (10 μM) for another 
6 h. After the compound treatment, we harvested the cells and analyzed the autofluorescence of the 
DOX using a flow cytometer.  
2.3. Rhodamine123 (Rho123) Efflux Assay 
For the Rho123 efflux assay, the MCF-7/ADR cell line was pretreated with different 
concentrations of XN (0–40 μM) for the first 34 h, after which with 10 μM Rho123 for two hours. The 
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2. Materials and Methods
2.1. Reagents and Cells
Nanjing Spring and Autumn Biological Engineering Co., Ltd., Nanjing, China, rov ded the
compound XN. The kit for Pgp-Glo™ ATPase assay was obtained from Promega Corporation,
Madison, WI, USA. Other materials were purchased from Beyotime Biotechnology, Shanghai, China.
The doxorubicin resistance MCF-7/ADR cell line was established by increasing DOX concentrations in
the culture medium of MCF-7 until reaching a concentration of 0.5 µM, as previously described [10].
The MCF-7/ADR cell line was cultured at Roswell Park Memorial Institute (RPMI)-1640, supplemented
with 10% fetal bovine serum (FBS), and maintained in the presence of DOX, penicillin, and streptomycin
at 37 ◦C in 5% CO2.
2.2. Detection of Intracellular DOX Accumulation
For the intra ellular DOX accumulation assay, th MCF-7/ADR cell line was pretreated with
different concentration of XN (0–20 µM) for 34 h and then co-incubated with DOX (10 µM) for another
6 h. After the compound treatment, we harvested the cells and analyzed the autofluorescence of the
DOX using a flow cytometer.
2.3. Rhodamine123 (Rho123) Efflux Assay
For the Rho123 efflux assay, the MCF-7/ADR cell line was pretreated with different concentrations
of XN (0–40 µM) for the first 34 h, after which with 10 µM Rho123 for two hours. The intracellular
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Rho123 was detected using flow cytometry (with an excitation wavelength of 488 nm and emission
wavelength of 530 nm).
2.4. ABCB1 ATPase Activity Assay
The ATPase activity of ABCB1 was assayed using a Pgp-Glo™ kit, according to the protocol
provided by the manufacturer. Verapamil (200 µM), which acts as a positive control, and the tested
compound XN (0–40 µM), were mixed with 25 µg ABCB1 and MgATP (5 mM) for 40 min at 37 ◦C.
Then, the concentration of ATP remaining in the reaction system was measured. The ATPase activity
of ABCB1 treated with XN or verapamil was compared to the basal ABCB1 ATPase activity.
2.5. Drug Synergism Calculation
The cell line was cultured with colchicine (COL) alone, XN alone, or COL and XN together. After
72 h treatment, a proliferation assay was carried out. Synergism between the two drugs was evaluated
as described previously [11]. Calcusyn was used to calculate the combination index (CI). CI values < 1
indicated a synergistic effect, CI values = 1 indicated an additive effect, and CI values > 1 indicated an
antagonistic effect.
2.6. Molecular Docking
Model generation, ligand preparation, docking, and molecular dynamics (MD) were conducted
using Schrödinger Suite 2015. A mouse ABCB1a crystal structure (PDB ID: 4Q9I) [12] was used to
construct a human ABCB1 homology model. Maestro Elements was used to prepare the ligands.
A 2D sketcher was employed to draw the DOX and XN 2D structures. Epik was used to generate
the ionization/tautomeric states pH 7, and select the lowest ionization/tautomeric states. To relax
the ligand structure, minimization was used. ADP from a maltose transporter (PDB ID: 3PUV) was
modified to ATP before transfer into the 4Q9I crystal structure. The ABCB1 (4Q9I) nucleotide binding
domain (NBD) was structurally assigned with the NBD of the maltose transporter (3PUV), and two
ATP molecules from 3PUV were incorporated into 4Q9I. Glide XP docking followed by induced fit
docking (IFD) was used to dock DOX and XN into the transmembrane domain. For Glide XP ligand
docking, from the prepared proteins, the protein grid files were generated, where the crystal ligand
(QZ-Ala) centroid was employed to determine the active site. A Glide XP scoring function was used to
dock the ligands DOX and XN separately into the generated grid. The obtained complexes from the
Glide XP docking were further subjected to IFD to obtain the final complexes (Figure S1).
2.7. Molecular Dynamics Simulations and Analysis
2.7.1. Simulation System Setup
IFD was applied to generate the structural models of protein-ligand complexes as the starting
conformation for MD simulations. Each of the docked complex models was first placed in a
membrane of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) lipid-bilayer, then solvated
in an orthorhombic water box with a buffer distance of 10 Å using the simple point-charge (SPC)
water model. The constructed tri-phase model systems were further neutralized using Na+ ions
by adding NaCl salt at a concentration of 0.15 M. The OPLS3 force field was used in docking and
system preparation.
2.7.2. System Relaxation and MD Simulations
For each of the two prepared systems, the model was first relaxed using the Desmond module,
following the default protocol for membrane protein relaxation [13]. A 1000-ns constant-temperature,
constant-pressure (NPT) MD simulation was then launched as the production run. Specifically, the
temperature was kept at 310 K using the Nosé–Hoover chain coupling scheme [14] with a coupling
constant of 1 ps. The pressure was maintained at 1 bar using the Martyna–Tuckerman–Klein chain
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coupling scheme [14] with a coupling constant of 2 ps. All bonds connecting hydrogen atoms were
constrained using M-SHAKE [13] to enable 2-fs time step simulations. The long-range electrostatic
interaction was treated by the k-space Gaussian split Ewald method [14] under periodic boundary
conditions (charge grid spacing, ~1.0 Å; direct sum tolerance, 10–9). While the cutoff distance for
short-range non-bonded interactions was set to 9 Å, the long-range Van der Waals (VDW) interaction
cutoff was based on uniform density approximation. Non-bonded forces were calculated using an
r-RESPA integrator [15], where the short-range forces were updated each step, and the long-range
forces were updated every three steps. The simulation trajectories were saved at 50-ps intervals.
2.7.3. Simulation Interaction Diagrams (SID)
Simulation trajectories were analyzed to explore the protein–ligand interactions using the Desmond
SID tool. Specifically, root mean square deviation (RMSD; Figure S2), root mean square fluctuation
(RMSF), secondary structure changes (Figure S3), protein-ligand contacts (Figures S4 and S5), and
ligand torsion profiles (Figure S6), were derived from the simulation results.
2.7.4. Convergence of Simulations
We checked the convergence of each MD simulation trajectory by analyzing the protein Cα and
ligand RMSD plots (Figure S2). The relatively stable RMSD within the last 200 ns indicated that the
complex systems reached a steady state at the later simulation stage.
2.7.5. MM-GBSA Binding Energies
For each system, the molecular mechanics/generalized Born surface area (MM-GBSA) binding
energy was calculated based on the last 200 ns simulation results. The OPLS3 force field, VSGB 2.0
solvation model, and the default Prime parameter were used for the MM-GBSA calculations, which
consisted of three calculation steps: receptor alone minimization, ligand alone minimization, and
receptor–ligand complex minimization. The total binding free energy was finally calculated as
∆G(bind) = Ecomplex(minimized) − (Eligand(minimized) + Ereceptor(minimized)). For each of the minimization
steps, three energy components were analyzed, including Eelectrostatics(Hbond + Ecoulomb + EGB_solvation),
EvdW (EvdW + Eπ−π stacking + Eself-contact), and Elipophilic.
2.8. Data Analysis
One-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was used for the
statistical analysis of the data. Data were expressed as means ± standard deviations (SD). p < 0.05 was
considered statistically significant.
3. Results
3.1. XN Inhibited the Efflux Functions of ABCB1 in MCF-7/ADR Cells
Our previous works have revealed XN exhibits significant synergistic effects with DOX [8].
To determine whether XN could modulate ABCB1 efflux function, we measured the intracellular DOX
concentration when treated or untreated with XN using flow cytometry. Our results showed that there
was only a little intracellular DOX when treated with XN, whereas XN concentration-dependently
increased DOX accumulation intracellularly (Figure 2A), suggesting that XN was able to decrease
DOX efflux.
We further confirmed that XN inhibited ABCB1 transport functions via evaluation of the efflux of
the ABCB1 substrate, Rho123, from MCF-7/ADR cells. As shown in Figure 2B, XN could significantly
and concentration-dependently increase the intracellular Rho123 concentration, emphasizing that XN
could inhibit the efflux function of ABCB1.
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Figure 2. XN blocks the efflux function of ABCB1 in MCF-7/ADR cells. (A) XN affects the intracellular
doxorubicin (DOX). The cells were treated with different concentrations of XN (0–40 µM) and then
10 µM DOX. The autofluorescence of DOX in MCF-7/ADR was as described in the materials and
methods section. Histograms show the intracellular DOX autofluorescence, * p < 0.05, ** p < 0.01, vs.
the control group; (B) Effect of XN on the efflux of the ABCB1 sub trate, Rho123. After XN treatment,
follow d by co-incubation with Rho123, intracellular Rho123 fluorescence was detected. The relative
mean fluorescence of Rho123 is shown in histograms, * p < 0.05, ** p < 0.01, vs. the control group.
3.2. XN Was a Substr te of ABCB1 and Stimulated Its ATPase Activity
Next, we evaluated the effects of XN on ABCB1-mediated ATP hydrolysis. The positive control,
verapamil, which is a classic substrate of ABCB1, showed ABCB1 substrate characteristics (Figure 3A)
and stimulated ABCB1 ATPase activity (Figure 3B). Similarly, XN showed classic ABCB1 substrate
characteristics (Figure 3A) and stimulated ABCB1 ATPase activity (Figure 3B). This result suggests that
XN might be a substrate of ABCB1, which could competitively inhibit ABCB1-mediated DOX transport.
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Figure 3. XN is a substrate of ABCB1 and stimulates its ATPase activity. (A) XN shows ABCB1 substrate
characteristics; (B) XN stimulates ABCB1 ATPase activity. The assay was performed as described in the
materials and methods section. * p < 0.05, ** p < 0.01, vs. the basal control group.
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3.3. XN Showed a Synergic Effect with COL in MCF-7/ADR Cells
To further confirm that XN is a substrate of ABCB1, we examined whether XN could increase
the cytotoxicity of the ABCB1 substrate, COL, in MCF-7/ADR cells. Neither COL nor XN alone
had significant inhibitory effects against cell viability at the indicated concentrations; however, when
administrated with XN, COL could remarkably inhibit the growth of MCF-7/ADR cells (Figure 4A). We
then conducted an isobolographic analysis and evaluated the synergistic effects. As shown in Figure 4B
and Table 1, COL in combination with XN at 1 and 2 µM, resulted in strong synergism between XN,
as evidenced by CI values < 1, and in addition, the synergistic effects increased with increasing
concentrations of XN. This result is supported by our published results showing XN exhibited synergic
effects with DOX (also a ABCB1 substrate) in MCF-7/ADR cells [8]. Taken together, we confirmed that
XN is a substrate of the ABCB1 transporter.
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cells. (A) MCF-7/ADR cells trea ed with 0.6 µM COL alone, 2 µM alone, or both; (B) Synergisms
analyzed by median effect plot using the s ft re, Calcusyn. MCF-7/ADR cells were co-treated with
COL and XN (0.5, 1, and 2 µM) for 72 h, the proliferation inhibition was detected, and the combination
index (CI) values were obtained.
Table 1. CI values of the combination between xanthohumol (XN) and colchicin (COL) in
MCF-7/ADR cells.
XN (µM) DOX (µM) Effect CI
0.5 0.08 0.03 0.79
0.5 0.16 0.04 1.17
0.5 0.31 0.08 1.28
0.5 0.63 0.23 1.04
0.5 1.25 0.47 0.93
0.5 2.5 0.79 0.65
0.5 5.0 0.90 0.69
1 0.08 0.06 0.58
1 0.16 0.06 0.95
1 0.31 0.1 1.16
1 0.63 0.21 1.16
1 1.25 0.49 0.89
1 2.5 0.79 0.66
1 5.0 0.89 0.75
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Table 1. Cont.
XN (µM) DOX (µM) Effect CI
2 0.08 0.09 0.55
2 0.16 0.10 0.76
2 0.31 0.16 0.86
2 0.63 0.28 0.94
2 1.25 0.53 0.82
2 2.5 0.80 0.64
2 5.0 0.90 0.70
3.4. XN Bound to the Central Transmembrane Domain (TMD) Site, Overlapping with the DOX Binding Site
To probe the interactions between the ligands (DOX and XN) and ABCB1, two ABCB1-ligand-ATP
complexes and 1000-ns MD simulations for each system were constructed. Our RMSD analysis
indicated the convergence of the MD simulations in the last 400 ns for both systems (Figure S2). The
detailed results of the protein secondary structure, protein–ligand contacts, and ligand torsion profiles
are provided in the supporting material (Figures S3–S6). Here, we highlight some key observations.
First, DOX and XN bound to similar central TMD sites. Figure 5A–C shows the superimposed
structures containing the ligands from the last frames of the two MD simulations. It is noteworthy
that the ligands DOX (red) and XN (blue) overlapped in the central TMD site. Figure 5D,E show the
binding of DOX and XN to nearby residues in the central TMD site, respectively. DOX bound close to
the residues Ile 340, Phe 983, Asn 839, Gln 990, Tyr 307, Gln 725, and Phe 343 (Figure 5D and Table S1).
XN bound close to residues Phe 336, Phe 983, Ala 980, Phe 728, Asn 842, Tyr 953, and Phe 732 (Figure 5E
and Table S1). The binding sites of XN overlapped with that of DOX, which suggested XN could block
DOX and interact to ABCB1 competitively. Second, MM-GBSA binding energy data (Table 2) showed
the binding of XN (−88.0 ± 6.3 kcal/mol) to the transporter at the central TMD site was stronger than
that of DOX (−86.1 ± 8.6 kcal/mol) by −1.9 kcal/mol. The energy decomposition indicated that the
hydrophobic interaction (∆∆Lip = −10.7 kcal/mol) was the major contributor to the energy difference
(−1.9 kcal/mol) between the two ligands. This hydrophobic interaction could be reduced by the VDW
interaction (∆∆VDW = 6 kcal/mol), and electrostatic interaction (∆∆GBELE = 2.9 kcal/mol). Third,
both the protein (Figure 6) and ligand RMSF analyses (Figure 7) showed that the DOX-protein system
had slightly higher position fluctuation than the XN-protein system. The average protein RMSF for
the DOX complex was 4.51 Å, whereas the protein RMSF for the XN complex was 2.89 Å. Similarly,
the average ligand RMSF for DOX was 2.58 Å, whereas the average ligand RMSF for XN was 1.85 Å.
The XN complex experienced less fluctuation overall, compared to the DOX complex. This could
indicate a more stable ligand–protein complex, providing evidence that XN bound to ABCB1 and
acted as a competitive inhibitor of DOX.
Table 2. MM-GBSA binding energies.
ABCB1/Inhibitor Complex ∆VDW ∆GBELE ∆LIPO ∆TOT ∆∆TOT
XN Complex −51.6 ± 3.2 14.3 ± 3.2 −50.7 ± 3.1 −88.0 ± 6.3 −1.9
DOX Complex −57.5 ± 3.4 11.4 ± 6.5 −39.9 ± 3.0 −86.1 ± 8.6 0.0
∆VDW = Change in VDW energy in gas phase upon complex formation (Units: kcal/mol); ∆GBELE = Change in
GB reaction field energy + gas phase Elec. energy upon complex formation (Units: kcal/mol); ∆LIPO = Change in
lipophilic term (lipophilic energy) upon complex formation (Units: kcal/mol); ∆TOT = ∆VDW + ∆LiPO + ∆GBELE
Change in potential energy in water upon complex formation (Units: kcal/mol).
Appl. Sci. 2018, 8, 681 8 of 11
Appl. Sci. 2018, 8, x FOR PEER REVIEW  8 of 11 
 
Figure 5. Structural representation of the predicted interaction between ABCB1 and its ligands. (A) 
Superimposed ABCB1 models from the last snapshot of the MD simulations. The model with DOX 
and ATP ligands is represented using red ligands in VDW and pink-colored ribbons. The model with 
XN and ATP ligands is represented using blue ligands in VDW and yellow-colored ribbons; (B) Close-
up view of the superimposed DOX and XN complexes at the ABCB1 central TMD from the top. DOX 
is shown in red and XN is shown in blue; (C) Close-up view of the superimposed complexes of DOX 
and XN at the central TMD of ABCB1 from the bottom; (D) Protein–ligand interactions between DOX 
and nearby residues in the central TMD site; (E) Protein–ligand interactions between XN and nearby 
residues in the central TMD site. 
 
Figure 6. Protein Root Mean Square Fluctuation (RMSF). Protein RMSF was used to characterize local 
changes along the protein chain. Peaks indicate areas of the protein that fluctuated the most during 
the simulation. The average RMSF for the DOX complex was 4.51 Å . The average RMSF for the XN 
complex was 2.89 Å . 
Figure 5. Structural representation of the predicted interaction between ABCB1 and its ligands.
(A) Superimposed ABCB1 models from the last snapshot of the MD simulations. The model with
DOX and ATP ligands is represented using red ligands in VDW and pink-colored ribbons. The model
with XN and ATP ligands is represented using blue ligands in VDW and yellow-colored ribbons;
(B) Close-up view of the superimposed DOX and XN complexes at the ABCB1 central TMD from the
top. DOX is shown in red and XN is shown in blue; (C) Close-up view of the superimposed complexes
of DOX and XN at the central TMD of ABCB1 from the bottom; (D) Protein–ligand interactions between
DOX and nearby residues in the central TMD site; (E) Protein–ligand interactions between XN and
nearby residues in the central TMD site.
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Figure 6. Protein Root Mean Square Fluctuation (RMSF). Protein RMSF was used to characterize local
changes along the protein chain. Peaks indicate areas of the protein that fluctuated the most during
the simulation. The average RMSF for the DOX complex was 4.51 Å. The average RMSF for the XN
complex was 2.89 Å.
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Figure 7. Ligand Root Mean Square Fluctuation (RMSF). (A) DOX atom reference; (B) XN atom
reference; (C) Ligand RMSF is used to characterize changes in the ligand atom positions. The graph
shows the ligand’s fluctuations broken down by atom, corresponding to the 2D structure. Ligand
RMSF was measured on the ligand heavy atoms after first being aligned on the protein backbone.
The average RMSF for DOX ligand was 2.58 Å. The average RMSF for the XN ligand was 1.85 Å.
4. Discussion
XN is a bioactive prenylated flavonoid compound uniquely distributed in the female inflorescences
of Humulus lupulus L., a well-known bittering agent in the brewing industry. In recent years, XN has
received much attention for its biological effects, especially in the anticancer area. A large amount
of research has shown that XN can prevent and treat cancers. The related mechanisms underlying
this anticancer activity have been revealed, including chemopreventive activity by inhibition of the
initiation and development of carcinogenesis, and therapeutic activity by proliferation inhibition,
apoptosis induction, migration inhibition, as well as angiogenesis inhibition [4].
Most recently, studies have shown that in MCF-7/ADR cells XN could reverse DOX resistance.
The underlying mechanisms of this are related to the signal transduction and activation of transcription
3 (STAT3) and epidermal growth factor receptor (EGFR) suppression [7], as well as MCF-7/ADR cell
stemness reduction [8]. ABCB1 plays a vital role in drug resistance by stimulating drug efflux. In this
study, we investigated, for the first time, whether XN could modulate ABCB1 efflux functions. Our
present results showed that XN decreased ABCB1 transporting functions, as evidenced by the increased
intracellular accumulation of ABCB1 substrates, DOX and Rho123. Subsequent molecular experiments
showed that XN was a substrate of ABCB1, which suggests that XN mediated-reversal of DOX
resistance might be related to ABCB1 activity modulation. The finding that XN was a substrate and
inhibitor of ABCB1, together with the previous finding that XN was also an inhibitor and substrate
of transporter ABCG2 [9], strongly supports its efficiency in the regulation of the efflux of chemical
drugs and exogenous compounds via affecting ABC transporters and its potential use for the reversal
of anticancer drug resistance. Since ABCB1 is also expressed in the intestine, inhibition of ABCB1
transport function might enhance the intestinal absorption of drugs.
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Results of molecular modeling and simulation showed the detailed interactions between the
ligands (XN and DOX) and ABCB1 and explained the molecular basis for the competitive inhibition
of DOX efflux by XN. XN bound to ABCB1 at the central TMD site, which overlapped with the
DOX binding site. In addition, XN binding affinity was stronger than that of DOX, resulting in less
protein and ligand position fluctuation. These results support that XN competitively blocked DOX
binding and efflux by ABCB1. However, further studies, including mutagenesis studies, are needed to
experimentally confirm the XN-ABCB1 interactions predicted by molecular docking and simulation.
5. Conclusions
In summary, we showed, for the first time, that the prenylated flavonoid, XN, was a substrate and
inhibitor of ABCB1. XN competitively bound to the DOX binding site in ABCB1 and, thus, inhibited
DOX efflux. Our study provided another mechanism underlying the reversal of ABCB1-mediated MDR
by XN and showed its potential use to reverse drug resistance and enhance drug intestinal absorption.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3417/8/5/681/s1.
Acknowledgments: This work was funded by the Natural Science Foundation of China (No. 41576187), Key
Research and Development Program of Shandong Province (No. 2016YYSP017, 2016ZDJS06A03, 2017GHY15112),
Natural Science Foundation of China-Shandong Joint Fund (No. U1606403), and Open Research Fund of State
Key Laboratory of Biological Fermentation Engineering of Beer (No. K2014002). We also acknowledge the
High Performance Computing Facility at Rowan, funded by the National Science Foundation under the Grant
MRI-1429467 and XSEDE MCB160164/160173/170088. The Anton2 machine at the Pittsburgh Supercomputing
Center (PSCA17017P) was generously made available by D. E. Shaw Research.
Author Contributions: J.M. and M.L. conceived and designed the experiments; F.L., J.D., H.L., H.Y., F.M. and
Z.Q. performed the experiments; F.L., J.M., M.L. and C.W. wrote the manuscript; statistical analysis was by
Mary Lesperance. C.W. designed the modeling part; and H.H. carried out the modeling part. All authors
approved the final manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Aller, S.G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P.M.; Trinh, Y.T.; Zhang, Q.;
Urbatsch, I.L.; et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding.
Science 2009, 323, 1718–1722. [CrossRef] [PubMed]
2. Safar, Z.; Vasko, B.; Ritchie, T.K.; Imre, G.; Mogyorosi, K.; Erdo, F.; Rajnai, Z.; Fekete, Z.; Szeremy, P.;
Muka, L.; et al. Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In Vitro and
In Vivo Assay Design. Curr. Drug Metab. 2016, 17, 430–455. [CrossRef] [PubMed]
3. Eichhorn, T.; Efferth, T. P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese
herbs. J. Ethnopharmacol. 2012, 141, 557–570. [CrossRef] [PubMed]
4. Liu, M.; Hansen, P.E.; Wang, G.; Qiu, L.; Dong, J.; Yin, H.; Qian, Z.; Yang, M.; Miao, J. Pharmacological
profile of xanthohumol, a prenylated flavonoid from hops (Humulus lupulus). Molecules 2015, 20, 754–779.
[CrossRef] [PubMed]
5. Nuti, E.; Bassani, B.; Camodeca, C.; Rosalia, L.; Cantelmo, A.; Gallo, C.; Baci, D.; Bruno, A.; Orlandini, E.;
Nencetti, S.; et al. Synthesis and antiangiogenic activity study of new hop chalcone Xanthohumol analogues.
Eur. J. Med. Chem. 2017, 138, 890–899. [CrossRef] [PubMed]
6. Albini, A.; Dell’Eva, R.; Vene, R.; Ferrari, N.; Buhler, D.R.; Noonan, D.M.; Fassina, G. Mechanisms of the
antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets. FASEB J. 2006, 20,
527–529. [CrossRef] [PubMed]
7. Kang, Y.; Park, M.A.; Heo, S.W.; Park, S.Y.; Kang, K.W.; Park, P.H.; Kim, J.A. The radio-sensitizing effect of
xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast
cancer cells. Biochim. Biophys. Acta (BBA) Gen. Subj. 2013, 1830, 2638–2648. [CrossRef] [PubMed]
8. Liu, M.; Yin, H.; Qian, X.; Dong, J.; Qian, Z.; Miao, J. Xanthohumol, a prenylated chalcone from hops, inhibits
the viability and stemness of doxorubicin-resistant MCF-7/ADR cells. Molecules 2016, 22, 36. [CrossRef]
[PubMed]
Appl. Sci. 2018, 8, 681 11 of 11
9. Tan, K.W.; Cooney, J.; Jensen, D.; Li, Y.; Paxton, J.W.; Birch, N.P.; Scheepens, A. Hop-derived prenylflavonoids
are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
Mol. Nutr. Food Res. 2014, 58, 2099–2110. [CrossRef] [PubMed]
10. Fairchild, C.R.; Ivy, S.P.; Kao-Shan, C.S.; Whang-Peng, J.; Rosen, N.; Israel, M.A.; Melera, P.W.; Cowan, K.H.;
Goldsmith, M.E. Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human
breast cancer cells. Cancer Res. 1987, 47, 5141–5148. [PubMed]
11. Chou, T.C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple
drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22, 27–55. [CrossRef]
12. Szewczyk, P.; Tao, H.; McGrath, A.P.; Villaluz, M.; Rees, S.D.; Lee, S.C.; Doshi, R.; Urbatsch, I.L.; Zhang, Q.;
Chang, G. Snapshots of ligand entry, malleable binding and induced helical movement in P-glycoprotein.
Acta Crystallogr. Sect. D Biol. Crystallogr. 2015, 71, 732–741. [CrossRef] [PubMed]
13. Gu, Y.; Qi, C.; Sun, X.; Ma, X.; Zhang, H.; Hu, L.; Yuan, J.; Yu, Q. Arctigenin preferentially induces tumor cell
death under glucose deprivation by inhibiting cellular energy metabolism. Biochem. Pharmacol. 2012, 84,
468–476. [CrossRef] [PubMed]
14. Ikeguchi, M. Partial rigid-body dynamics in NPT, NPAT and NP gamma T ensembles for proteins and
membranes. J. Comput. Chem. 2004, 25, 529–541. [CrossRef] [PubMed]
15. Stuart, S.J.; Zhou, R.H.; Berne, B.J. Molecular dynamics with multiple time scales: The selection of efficient
reference system propagators. J. Chem. Phys. 1996, 105, 1426–1436. [CrossRef]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
